Brief: Panbela Announces Adoption Of Commission Implementing Decision From The EMA For The Orphan Designation Of Ivospemin (Sbp-101) In Combination With Gemcitabine And NAB-Paclitaxel
19/01/2023 14:01
Jan 19 (Reuters) - Panbela Therapeutics Inc PBLA.O :
* PANBELA ANNOUNCES ADOPTION OF COMMISSION IMPLEMENTING
DECISION
FROM THE EMA FOR THE ORPHAN DESIGNATION OF IVOSPEMIN (SBP-101)
IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS
WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
* PANBELA - CONTINUING TO FOCUS ON SITE INITIATION &
ENROLLMENT IN
ASPIRE TRIAL TO ULTIMATELY DELIVER A MORE EFFECTIVE TREATMENT
FOR PANCREATIC CANCER
* PANBELA THERAPEUTICS INC - EXPECTS THAT FULL COMPLEMENT OF
SITES
WILL BE OPEN BY MID 2023
Source text for Eikon: ID:nGNE8rkpbD
Further company coverage: PBLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants